Cardiovascular

Patient sample and mouse studies suggest inhibiting LOXL2 could help treat heart failure. LOXL2 levels were higher in serum samples from heart failure patients and cardiac tissue samples from cardiomyopathy patients than in serum and cardiac tissue samples from healthy volunteers, respectively. In a mouse model of transaortic constriction-induced heart failure, LOXL2 knockout or an anti-LOXL2 mAb decreased cardiac fibrosis and increased cardiac function compared with normal LOXL2 expression or a control IgG. Next steps could include testing LOXL2 inhibitors in additional models of heart failure...